Question: if an mHSPC patient has a PSA decline on primary treatment to <0.2ng/mL, does the volume of metastases at diagnosis make a difference? Answer in our latest STAMPEDE trial manuscript eur01.safelinks.protection.outlook.com/?url=https%3A%…
AttardLab
@AttardLab
Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.
243 Following 1.2K Followers 248 Posts
Latest posts 5
How can we prevent the aggressive disease course of PTEN loss/inactive cancers? @EmilyGrist1 @ChrisSweens1 eur01.safelinks.protection.outlook.com/?url=https%3A%…
Publication of CAPItello-281 Ph 3 trial in @Annals_Oncology at end of @fizazi_karim #ESMO25 👍annalsofoncology.org/article/S0923-…
EnzaRad P3 trial confirms boundary of patient benefit sits somewhere between STAMPEDE ultra HR and NCCN HR. Working together we will use BM to define this #ESMO25
STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.